Morgan Stanley’s cbdMD, Inc. 8.0% Series A Cumulative Convertible Preferred Stock YCBD.PRA Stock Holding History

Morgan Stanley’s Portfolio YCBD.PRA Stock Details YCBD.PRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-700	Closed	-$945	–	8339
2025 Q1	$945	Hold	700	–	–	﹤0.01%	7288
2024 Q4	$546	Hold	700	–	–	﹤0.01%	7336
2024 Q3	$420	Hold	700	–	–	﹤0.01%	7319
2024 Q2	$434	Hold	700	–	–	﹤0.01%	7243
2024 Q1	$580	Sell	700 -4,700	-87%	-$3.14K	﹤0.01%	7226
2023 Q4	$3.78K	Buy	5,400 +2,700	+100%	+$2.56K	﹤0.01%	7049
2023 Q3	$3.24K	Hold	2,700	–	–	﹤0.01%	7013
2023 Q2	$8.51K	Hold	2,700	–	–	﹤0.01%	6865
2023 Q1	$9.02K	Hold	2,700	–	–	﹤0.01%	6913
2022 Q4	$10.9K	Buy	2,700 +200	+8%	+$799	﹤0.01%	6897
2022 Q3	$9K	Hold	2,500	–	–	﹤0.01%	7125
2022 Q2	$9K	Hold	2,500	–	–	﹤0.01%	7255
2022 Q1	$14K	Buy	2,500 +1,700	+213%	+$9.09K	﹤0.01%	7291
2021 Q4	$5K	Buy	+800	New	+$4.89K	﹤0.01%	7658

Morgan Stanley's YCBD.PRA Position: Q2 2025 in Review

Morgan Stanley sold out of cbdMD, Inc. 8.0% Series A Cumulative Convertible Preferred Stock (YCBD.PRA) in Q2 2025, closing a stake of 700 shares — an estimated $945 sold.

Morgan Stanley first reported a position in YCBD.PRA in Q4 2021 and held it in 14 quarters. The position peaked at $14K in Q1 2022. 0 funds tracked by Wall St. Rank hold YCBD.PRA as of Q2 2025.

Morgan Stanley reported no remaining cbdMD, Inc. 8.0% Series A Cumulative Convertible Preferred Stock position as of Q2 2025 after selling out during the quarter.
Morgan Stanley sold 700 cbdMD, Inc. 8.0% Series A Cumulative Convertible Preferred Stock shares in Q2 2025, an estimated $945.
Morgan Stanley first reported a position in cbdMD, Inc. 8.0% Series A Cumulative Convertible Preferred Stock in Q4 2021 and held it in 14 quarters.
Morgan Stanley's cbdMD, Inc. 8.0% Series A Cumulative Convertible Preferred Stock position peaked at $14K in Q1 2022.
0 funds tracked by Wall St. Rank held cbdMD, Inc. 8.0% Series A Cumulative Convertible Preferred Stock as of Q2 2025.

Based on Morgan Stanley's 13F filing for Q2 2025, filed 15 Aug 2025.